-
May 2024
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.
J Clin Endocrinol MetabPribitzer S, O'Rourke C, Ylescupidez A, Smithmyer M, Bender C, Speake C, Lord S, Greenbaum CJ -
Nov 2023
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.
Nat CommunYlescupidez A, Bahnson HT, O'Rourke C, Lord S, Speake C, Greenbaum CJ -
Aug 2023
OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals.
J Clin Endocrinol MetabYlescupidez A, Speake C, Pietropaolo SL, Wilson DM, Steck AK, Sherr JL, Gaglia JL, Bender C, Lord S, Greenbaum CJ -
Mar 2023
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Nat CommunJaycox JR, Lucas C, Yildirim I, Dai Y, Wang EY, Monteiro V, Lord S, Carlin J, Kita M, Buckner JH, Ma S, Campbell M, Ko A, Omer S, Lucas CL, Speake C, Iwasaki A, Ring AM -
Jan 2023
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.
J Endocr SocKinney M, You L, Sims EK, Wherrett D, Schatz D, Lord S, Krischer J, Russell WE, Gottlieb PA, Libman I, Buckner JH, DiMeglio LA, Herold K, Steck A -
Oct 2022
IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.
JCI InsightSpeake C, Habib T, Lambert K, Hundhausen C, Lord S, Dufort MJ, Skinner SO, Hu A, Kinsman M, Jones BE, Maerz MD, Tatum M, Hocking AM, Nepom GT, Greenbaum CJ, Buckner JH -
Oct 2022
Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.
J Clin Endocrinol MetabO'Rourke C, Ylescupidez A, Bahnson HT, Bender C, Speake C, Lord S, Greenbaum CJ -
Oct 2022
Recognition of mRNA Splice Variant and Secretory Granule Epitopes by CD4+ T Cells in Type 1 Diabetes.
DiabetesGuyer P, Arribas-Layton D, Manganaro A, Speake C, Lord S, Eizirik DL, Kent SC, Mallone R, James EA -
Mar 2022
Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients.
J ImmunolYuzefpolskiy Y, Morawski P, Fahning M, Speake C, Lord S, Chaudhary A, Morishima C, Wener MH, Kita M, McCarthy L, Buckner JH, Campbell DJ, Bettelli E -
Jan 2022
Characterising the age-dependent effects of risk factors on type 1 diabetes progression.
DiabetologiaSo M, O'Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, Bruggeman BS, Lord S, Greenbaum CJ, Speake C -
Jan 2022
Changing the Course of Disease in Type 1 Diabetes
VanBuecken D, Lord S, Greenbaum CJ, Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP -
Nov 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
JCI InsightGreenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. -
Jul 2020
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.
F1000ResLord S, Greenbaum CJ -
Jan 2019
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.
DrugsGreenbaum CJ, VanBuecken DE, Lord S -
Oct 2017
Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.
Curr Diab RepGreenbaum CJ, Lord S, VanBuecken DE
